Literature DB >> 19935656

DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity.

Jeremy D Henson1, Ying Cao, Lily I Huschtscha, Andy C Chang, Amy Y M Au, Hilda A Pickett, Roger R Reddel.   

Abstract

Alternative lengthening of telomeres (ALT) is likely to be an important target for anticancer treatment as approximately 10% of cancers depend on this telomere maintenance mechanism for continued growth, and inhibition of ALT can cause cellular senescence. However, no ALT inhibitors have been developed for therapeutic use because of the lack of a suitable ALT activity assay and of known ALT-specific target molecules. Here we show that partially single-stranded telomeric (CCCTAA)(n) DNA circles (C-circles) are ALT specific. We provide an assay that is rapidly and linearly responsive to ALT activity and that is suitable for screening for ALT inhibitors. We detect C-circles in blood from ALT(+) osteosarcoma patients, suggesting that the C-circle assay (CC assay) may have clinical utility for diagnosis and management of ALT(+) tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935656     DOI: 10.1038/nbt.1587

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  24 in total

1.  Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids.

Authors:  K Perrem; T M Bryan; A Englezou; T Hackl; E L Moy; R R Reddel
Journal:  Oncogene       Date:  1999-06-03       Impact factor: 9.867

Review 2.  Telomeres and their control.

Authors:  M J McEachern; A Krauskopf; E H Blackburn
Journal:  Annu Rev Genet       Date:  2000       Impact factor: 16.830

3.  Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Authors:  K Perrem; L M Colgin; A A Neumann; T R Yeager; R R Reddel
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

4.  Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.

Authors:  Clare L Fasching; Kylie Bower; Roger R Reddel
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

5.  Ku suppresses formation of telomeric circles and alternative telomere lengthening in Arabidopsis.

Authors:  Barbara Zellinger; Svetlana Akimcheva; Jasna Puizina; Martina Schirato; Karel Riha
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

6.  Unusual telomeric DNAs in human telomerase-negative immortalized cells.

Authors:  Akira Nabetani; Fuyuki Ishikawa
Journal:  Mol Cell Biol       Date:  2008-11-17       Impact factor: 4.272

7.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

Review 8.  Circulating nucleic acids in plasma/serum.

Authors:  Jason C H Tsang; Y M Dennis Lo
Journal:  Pathology       Date:  2007-04       Impact factor: 5.306

9.  Telomere dynamics in an immortal human cell line.

Authors:  J P Murnane; L Sabatier; B A Marder; W F Morgan
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

10.  Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres.

Authors:  Amra Grudic; Asne Jul-Larsen; Stuart J Haring; Marc S Wold; Per Eystein Lønning; Rolf Bjerkvig; Stig Ove Bøe
Journal:  Nucleic Acids Res       Date:  2007-10-24       Impact factor: 16.971

View more
  207 in total

1.  Telomerase activity in pleural malignant mesotheliomas.

Authors:  Amy Y M Au; Torben Hackl; Thomas R Yeager; Scott B Cohen; Harvey I Pass; Curtis C Harris; Roger R Reddel
Journal:  Lung Cancer       Date:  2011-01-31       Impact factor: 5.705

2.  Maintenance of very long telomeres by recombination in the Kluyveromyces lactis stn1-M1 mutant involves extreme telomeric turnover, telomeric circles, and concerted telomeric amplification.

Authors:  Jianing Xu; Michael J McEachern
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 3.  Telomere biology: Rationale for diagnostics and therapeutics in cancer.

Authors:  Philippe Rousseau; Chantal Autexier
Journal:  RNA Biol       Date:  2015-08-20       Impact factor: 4.652

4.  TZAP: A telomere-associated protein involved in telomere length control.

Authors:  Julia Su Zhou Li; Javier Miralles Fusté; Tatevik Simavorian; Cristina Bartocci; Jill Tsai; Jan Karlseder; Eros Lazzerini Denchi
Journal:  Science       Date:  2017-01-12       Impact factor: 47.728

5.  NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination.

Authors:  Dimitri Conomos; Roger R Reddel; Hilda A Pickett
Journal:  Nat Struct Mol Biol       Date:  2014-08-24       Impact factor: 15.369

6.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Authors:  Matthew Mistry; Nataliya Zhukova; Daniele Merico; Patricia Rakopoulos; Rahul Krishnatry; Mary Shago; James Stavropoulos; Noa Alon; Jason D Pole; Peter N Ray; Vilma Navickiene; Joshua Mangerel; Marc Remke; Pawel Buczkowicz; Vijay Ramaswamy; Ana Guerreiro Stucklin; Martin Li; Edwin J Young; Cindy Zhang; Pedro Castelo-Branco; Doua Bakry; Suzanne Laughlin; Adam Shlien; Jennifer Chan; Keith L Ligon; James T Rutka; Peter B Dirks; Michael D Taylor; Mark Greenberg; David Malkin; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Uri Tabori
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

7.  Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells.

Authors:  Mindy K Graham; Jiyoung Kim; Joseph Da; Jacqueline A Brosnan-Cashman; Anthony Rizzo; Javier A Baena Del Valle; Lionel Chia; Michael Rubenstein; Christine Davis; Qizhi Zheng; Leslie Cope; Michael Considine; Michael C Haffner; Angelo M De Marzo; Alan K Meeker; Christopher M Heaphy
Journal:  Mol Cancer Res       Date:  2019-10-14       Impact factor: 5.852

8.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 9.  Telomere recombination pathways: tales of several unhappy marriages.

Authors:  Neal F Lue; Eun Young Yu
Journal:  Curr Genet       Date:  2016-09-25       Impact factor: 3.886

10.  Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs.

Authors:  Thomas Winkler; So Gun Hong; Jake E Decker; Mary J Morgan; Chuanfeng Wu; William M Hughes; Yanqin Yang; Danny Wangsa; Hesed M Padilla-Nash; Thomas Ried; Neal S Young; Cynthia E Dunbar; Rodrigo T Calado
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.